Targeting the Wnt/beta-catenin pathway in multiple myeloma

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4719-4726

  Schmeel, Leonard Christopher ^a   Schmeel, Frederic Carsten ^a   Kim, Young ^a   Endo, Tomoyuki ^b   Lu, Desheng ^c   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Beta catenin; MPC 11; Myeloma; OPM 2; RPMI 8226; Signaling therapies; U 266 cell lines; Wnt inhibitors; Wnt pathway

Indexed keywords

BETA CATENIN; CICLOPIROXOLAMINE; ETACRYNIC ACID; PICEATANNOL; PROPIDIUM IODIDE; WNT PROTEIN;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; INTERMETHOD COMPARISON; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STAINING; WNT SIGNALING PATHWAY;

BETA-CATENIN; MPC-11; MYELOMA; OPM-2; RPMI-8226; SIGNALING THERAPIES; U-266 CELL LINES; WNT INHIBITORS; WNT PATHWAY;

ANIMALS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; COLON; DIURETICS; DRUG SYNERGISM; ETHACRYNIC ACID; FLOW CYTOMETRY; HUMANS; MICE; MULTIPLE MYELOMA; PROTEIN-TYROSINE KINASES; PYRIDONES; STILBENES; WNT PROTEINS;

EID: 84891362996     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Palumbo A and Anderson K: Multiple myeloma. N Engl J Med 364: 1046-1060, 2011.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62 (1): 10-29, 2012.
3. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds.). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
4. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
5. Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004.
6. Nusse R. Wnt signaling in disease and in development. Cell Res 15: 28-32, 2005.
7. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000
8. Willert K and Jones KA: Wnt signaling: is the party in the nucleus? Genes Dev 20: 1394-1404, 2006.
9. Aberle H, Bauer A, Stappert J, Kispert A and Kemler R: betacatenin is a target for the ubiquitin-proteasome pathway. EMBO J 16(13): 3797-3804, 1997.
10. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC and Carrasco DR: Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 114: 2699-708, 2009.
11. Qiang YW, Endo Y, Rubin JS and Rudikoff S: Wnt signaling in B-cell neoplasia. Oncogene 22: 1536-1545, 2003.
12. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC and Carrasco DR: Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104: 7516-7521, 2007.
13. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M and Pals ST: Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101: 6122-6127, 2004
14. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G and Golub TR: Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467-472, 2011.
15. Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S and Maekawa T: {beta}-Catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 15: 2731-2738, 2009.
16. Alas S and Bonavida B: Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 9(1): 316-326, 2003.
17. Kim Y, Gast SM, Endo T, Lu D, Carson D and Schmidt-Wolf IG: In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma. Leuk Res 36(5): 598-600, 2012.
18. Kim Y, Schmidt M, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo 25(6): 887-893, 2011.
19. Fowler JA, Mundy GR, Lwin ST and Edwards CM: Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 72(9): 2183-2189, 2012.
20. Kocemba KA, Groen RW, van Andel H, Kersten MJ, Mahtouk K, Spaargaren M and Pals ST: Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PLoS One 7(2): e30359, 2012.
21. Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598, 2007.
22. Schmidt M, Kim Y, Gast SM, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid. In Vivo 25(3): 325-333, 2011.
23. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ and Carson DA: Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 4 (12): e8294, 2009.
24. Takada Y and Aggarwal BB: TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-κB activation, and apoptosis. Journal of Immunology 173(2): 1066-1077, 2004.
25. Kim EJ, Park H, Park SY, Jun JG and Park JHY: The grape component piceatannol induces apoptosis in du145 human prostate cancer cells via the activation of extrinsic and intrinsic pathways. Journal of Medicinal Food 12(5): 943-951, 2009.
26. Hsieh TC, Lin CY, Lin HY and Wu JM: AKT/mTOR as novel targets of polyphenol piceatannol possibly contributing to inhibition of proliferation of cultured prostate cancer cells. ISRN Urology 2012: 272697, 2012.
27. Ko HS, Lee HJ, Kim SH and Lee EO: Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-kappaB pathways. Journal of Agricultural and Food Chemistry 60: 4083-4089, 2012.
28. Wolter F, Clausnitzer A, Akoglu B, Stein J. Piceatannol, a natural analog of resveratrol, inhibits progression through the s phase of the cell cycle in colorectal cancer cell lines. Journal of Nutrition 132(2): 298-302, 2002.
29. Belenky P, Camacho D and Collins JJ: Fungicidal drugs induce a common oxidative-damage cellular death pathway. Cell Rep 3(2): 350-358, 2013.
30. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick JE, Schimmer AD. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114(14): 3064-3073, 2009.
31. Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu B, Han X, Pang J, Rivera CA and Huang S: The antitumor activity of the fungicide ciclopirox. Int J Cancer 127(10): 2467-2477, 2010.
32. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M, Joseph B, Subramaniam R, Aman A, Chau A, Hogge DE, Weir SJ, Kasper J, Schimmer AD, Al-awar R, Wrana JL and Attisano L: Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res 71(24): 7628-7639, 2011.
33. Coombs GS, Schmitt AA, Canning CA, Alok A, Low IC, Banerjee N, Kaur S, Utomo V, Jones CM, Pervaiz S, Toone EJ and Virshup DM: Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 31(2): 213-225, 2012.
34. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48(13): 3622-3625, 1988.
35. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M and Tsuchida S: Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci 94 (10): 886-893, 2003.
36. Han Y, Englert JA, Delude RL and Fink MP: Ethacrynic acid inhibits multiple steps in the NF-kappaB signaling pathway. Shock 23(1): 45-53, 2005.